Overview
Clostridium difficile is an obligate anaerobic, Gram-positive, spore-forming bacillus and a major cause of antibiotic-associated diarrhea. It is a significant healthcare-associated pathogen, particularly linked with prolonged antimicrobial use. The organism produces two main exotoxins – Toxin A (enterotoxin) and Toxin B (cytotoxin)—which are responsible for intestinal damage. Infection with toxigenic strains can lead to a distinctive condition known as pseudomembranous colitis, which occurs almost exclusively following extended antibiotic therapy. Because mere colonization does not always indicate disease, toxin detection plays a crucial role in confirming active infection.
Symptoms
Diarrhea is the most common clinical manifestation of Clostridium difficile infection. Other associated symptoms include fever, abdominal pain, and leukocytosis. In severe cases, pseudomembranes form in the colon. These pseudomembranes are composed of necrotic leukocytes, fibrin, mucus, and cellular debris, and they adhere to the underlying mucosa, contributing to inflammation and tissue damage. The severity of symptoms may range from mild diarrhea to life-threatening colitis.
Causes
The primary cause of Clostridium difficile infection is disruption of normal gut flora due to long-term or broad-spectrum antibiotic use. This disruption allows ingestion and colonization of Clostridium difficile spores. Toxigenic strains then produce toxins TcdA and TcdB, and in some cases, the binary toxin (CDT), which inactivate Rho proteins, damage the intestinal barrier, and induce cell death and inflammation. The host immune response further amplifies the inflammatory process, leading to diarrhea and severe colonic complications such as pseudomembranous colitis.
Risk Factors
Several factors increase the risk of developing Clostridium difficile infection. These include prolonged hospital stay and extended use of antimicrobials such as cephalosporins (e.g., ceftriaxone), clindamycin, ampicillin, and fluoroquinolones (e.g., ciprofloxacin). Advanced age, particularly in individuals older than 65 years, significantly raises susceptibility. Additional risk factors include immunosuppression, cancer chemotherapy, and overall toxin production by virulent strains. These factors contribute to both the occurrence and recurrence of infection.
Prevention and Diagnostic Importance
Prevention of Clostridium difficile infection is closely linked to appropriate antibiotic stewardship and effective infection control practices. Laboratory diagnosis primarily relies on stool samples, specifically unformed stool collected in a leak-proof container. While stool culture using selective media such as CCFA and CCYA under anaerobic conditions is highly sensitive and specific, isolation alone is insufficient to confirm disease.
Toxin detection is more meaningful for diagnosis. Antigen detection methods include identification of glutamate dehydrogenase (GDH), a common antigen present in both toxigenic and non-toxigenic strains, and detection of Toxin A and B, which confirms toxigenic infection. Rapid immunochromatographic tests and enzyme immunoassays are commonly used. Automated tests such as ELFA-based assays and nucleic acid amplification tests (NAAT), including RT-PCR and LAMP, detect toxin-regulating genes with high sensitivity, though they may also identify asymptomatic carriers.
The cell culture cytotoxicity assay remains the gold standard for toxin detection due to its high sensitivity and specificity, despite longer turnaround time and complexity. Accurate toxin detection is clinically significant, as it guides diagnosis, treatment decisions, infection control measures, and helps reduce recurrence, morbidity, mortality, and healthcare costs.
